Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph - Poll - MDSpire

Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph

  • By

  • Su, Meiyi

  • Tang, Yuqing

  • Sun, Pengtao

  • Cen, Huan

  • Liu, Shaonan

  • Li, Xianlun

  • Wang, Wei

  • Wang, Lei

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-Enhanced Myocardial Contrast Echocardiograph

  • by Su, Meiyi , Tang, Yuqing , Sun, Pengtao , Cen, Huan , Liu, Shaonan , Li, Xianlun , Wang, Wei , Wang, Lei

  • June 10, 2026

Related Content

Preexisting Risk Drove Poststorm Events

Analysis of nearly 1.6 million veterans showed preexisting community health inequities largely explained poststorm cardiovascular and respiratory outcomes.

Systemic Inflammatory Response Induces Multi-Organ Damage After Cardiac Arrest Through IL-17 Pathway in Animal Models

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.